SC
OXFD

Scholtz & Company’s Oxford Immunotec Global PLC Ordinary Shares OXFD Stock Holding History

Scholtz & Company’s Portfolio OXFD Stock Details OXFD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-58,925
Closed -$990K – 73
2017
Q3 		$990K Buy
+58,925
New +$959K 0.77% 38

Other funds holding OXFD

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return

Scholtz & Company's OXFD Position: Q4 2017 in Review

Scholtz & Company sold out of Oxford Immunotec Global PLC Ordinary Shares (OXFD) in Q4 2017, closing a stake of 58,925 shares — an estimated $990K sold.

Scholtz & Company first reported a position in OXFD in Q3 2017 and held it in 1 quarter. The position peaked at $990K in Q3 2017. 77 funds tracked by Wall St. Rank hold OXFD as of Q4 2017.

  • Scholtz & Company reported no remaining Oxford Immunotec Global PLC Ordinary Shares position as of Q4 2017 after selling out during the quarter.
  • Scholtz & Company sold 58,925 Oxford Immunotec Global PLC Ordinary Shares shares in Q4 2017, an estimated $990K.
  • Scholtz & Company first reported a position in Oxford Immunotec Global PLC Ordinary Shares in Q3 2017 and held it in 1 quarter.
  • Scholtz & Company's Oxford Immunotec Global PLC Ordinary Shares position peaked at $990K in Q3 2017.
  • 77 funds tracked by Wall St. Rank held Oxford Immunotec Global PLC Ordinary Shares as of Q4 2017.

Based on Scholtz & Company's 13F filing for Q4 2017, filed 14 Feb 2018.